Clik here to view.
Waters Introduces Faster, Reliable and Automated Solution for Mass and Purity...
MILFORD, Mass. Waters Corporation (NYSE:WAT) today introduced new software and analytical columns to aid biomolecule drug discovery and development. The new Waters™ Intact Mass app on...
View ArticleClik here to view.
ウォーターズはバイオ医薬品の質量分析および純度分析用の高速かつ信頼性の高い自動化ソリューションを導入
マサチューセッツ州ミルフォード （ビジネスワイヤ） — ウォーターズコーポレーション (NYSE:WAT) は本日、バイオ医薬品の創薬と開発を支援する新しいソフトウェアおよび分析用カラムを発表しました。waters_connect™ の新しい Waters™ Intact Mass アプリケーションにより、BioAccord™ LC-MS...
View ArticleClik here to view.
沃特世推出更快速可靠的自动化解决方案，助力生物药物分子量和纯度分析
美国 马萨诸塞州米尔福德 沃特世公司（纽约证券交易所代码：WAT）近日推出全新软件和分析柱产品，旨在助力生物分子药物发现和开发。使用waters_connect平台新增的Waters Intact Mass应用程序，科学家们能够在BioAccord LC-MS系统上快速确认合成或重组工艺生成的生物分子和杂质分子量，其分析速度可达市场上其他产品的近两倍i。...
View ArticleClik here to view.
Qihan Biotechnology Presents Preclinical Data at American Association for...
HANGZHOU, China Hangzhou Qihan Biotechnology Co., Ltd, an innovative biotechnology company dedicated to applying genome editing technology to cell therapies and organ transplants, today announced...
View ArticleClik here to view.
GC Signs Definitive Agreement to Acquire US CDMO BioCentriq, Enhancing Global...
YONGIN, SOUTH KOREA & NEWARK, N.J. GC corp. (KOSPI: 005250), the holding (system) company for GC group in South Korea with major operating companies in across healthcare sectors, today announced...
View ArticleClik here to view.
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply...
View ArticleClik here to view.
Asian Fund for Cancer Research Announces Chimera Bioengineering as the 2021...
HONG KONG Chimera Bioengineering has been selected as the winner of the Asian Fund for Cancer Research’s (AFCR) 2021 BRACE Award Venture Competition—a first-of-its-kind program for early stage...
View ArticleClik here to view.
武田荣获2022年国际制药工程协会年度设施奖两项大奖
日本大阪和马萨诸塞州剑桥市 (美国商业资讯)—武田(Takeda, TSE:4502/NYSE:TAK)今天宣布，国际制药工程协会(ISPE)在2022年度设施奖 (FOYA)的供应链和Pharma 4.0™类别中授予公司最高荣誉。在供应链类别中，武田凭借为异体间充质干细胞疗法实施以患者为中心的新供应链而获奖；武田位于德国辛根的疫苗生产设施则在Pharma 4.0类别中获奖。...
View ArticleClik here to view.
Clik here to view.
NEXEL Earns the First ISO/IEC 17025:2017 Accreditation for iPSC-derived...
SEOUL, South Korea NEXEL, a global leader in induced pluripotent stem cell (iPSC) technology, announced today that it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the...
View ArticleClik here to view.
Embleema and CDISC Partner to Develop Standards for Cell and Gene Therapy...
METUCHEN, N.J. & AUSTIN, Texas Embleema Inc. and CDISC have announced a collaboration to develop new standards for experimental assays and bioinformatics protocols to facilitate monitoring the...
View ArticleClik here to view.
Megakaryon Corporation Initiates First-in-Human Clinical Trial of Allogenic...
KYOTO, Japan Megakaryon Corporation (hereinafter, Megakaryon) today announces its clinical trial of allogenic human iPSC-derived HLA homozygous platelets (Development Code: MEG-002) in collaboration...
View ArticleClik here to view.
New Data on Ropeginterferon Alfa-2b to Be Featured at EHA2022
TAIPEI PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology...
View ArticleClik here to view.
Quizartinib Plus Chemotherapy Significantly Improved Overall Survival...
TOKYO & BASKING RIDGE, N.J. Positive results from the global pivotal QuANTUM-First phase 3 trial of Daiichi Sankyo’s (TSE:5468) quizartinib combined with standard induction and consolidation...
View ArticleClik here to view.
AOP...
维也纳 (美国商业资讯)–AOP Health在著名的2022年欧洲血液学协会(EHA)年会上公布了Ropeginterferon alfa-2b（罗培根干扰素α-2b）治疗真性红细胞增多症(PV)患者的最终研究结果。奥地利维也纳医科大学的Heinz Gisslinger教授口头报告了结果1。 摘要链接 罗培根干扰素α-2b是一种长效型单聚乙二醇化脯氨酸干扰素(ATC...
View ArticleClik here to view.
AOPヘルスが真性多血症患者をBESREMi®（ロペグインターフェロンアルファ-2b）で最長7.5年間にわたり治療したCONTINUATION-PV試験の...
ウィーン （ビジネスワイヤ） — AOPヘルスは、権威ある欧州血液学会（EHA）の2022年度総会でオーストリアのウィーン医科大学のハインツ・ギスリンガー教授が口頭発表にて、真性多血症（PV）患者をロペグインターフェロンアルファ-2bで治療したCONTINUATION-PV試験の最終結果を報告したと発表しました1。 アブストラクトへのリンク...
View ArticleClik here to view.
Slingshot Biosciences, Inc. Partners With Chameleon Science to Distribute...
EMERYVILLE, Calif. SLINGSHOT BIOSCIENCES, INC., the developers of synthetic cells, today announced they have extended their distribution channel through a new agreement with Chameleon Science....
View ArticleClik here to view.
PHC株式会社：PHCbi、独自の電気化学式センサー技術を活用した研究用「ライブセル代謝分析装置」のプロトタイプを開発～細胞治療の産業化に向けた課題解決へ...
東京 （ビジネスワイヤ） — ライフサイエンス分野において研究・医療支援機器およびサービスをグローバルに提供するPHC株式会社 バイオメディカ事業部（以下、「PHCbi」）は、7月13日（水）から7月15日（金）まで東京ビッグサイトで開催される「第4回ファーマラボEXPO東京」（主催：RX...
View ArticleClik here to view.
Ozgene and Gen-H partner on Ozgene’s new OzBIG targeted humanization capability
PERTH, Australia & HEIDELBERG, Germany Ozgene and Gen-H are pleased to announce our working partnership supporting Ozgene’s new OzBIG capability. Ozgene Pty Ltd is a privately held CRO based in...
View ArticleClik here to view.
InnoCare Announces the Acceptance of the Biologics License Application for...
BEIJING InnoCare Pharma (HKEX: 09969) announced today the acceptance of the biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or...
View Article